Bayer
Bayer invests 35m euros in biologics production
December 14, 2010Manufacturing and Production Bayer, Germany, biologics, clinical trials supplies, pharma production
Bayer HealthCare is ramping up its biologics production capacity with the building of a new facility in Wuppertal, Germany, that …
Bayer’s challenger to Lucentis shows promise
November 22, 2010Research and Development, Sales and Marketing Bayer, Lucentis, Novartis, Regeneron, Roche, VEGF Trap-Eye, age-related macular degeneration, avastin, wet AMD
Phase III data for a new age-related macular degeneration (wet AMD) treatment show it is as good as Lucentis, the …
Bayer set for 4,500 job cuts
November 19, 2010Research and Development, Sales and Marketing Bayer, Cost cutting, emerging markets
Bayer has announced large scale job losses aimed at saving 800 million euro savings in the coming years.The cuts are …
Bayer faces ABPI audit after “shocking” Levitra error
November 5, 2010Medical Communications, Sales and Marketing ABPI, ABPI Code of Practice, Bayer, PMCPA
Bayer has been accused of a “shocking error of judgement” after promotional material for its erectile dysfunction brand Levitra (vardenafil) …
New form of Levitra wins EU approval
September 7, 2010Sales and Marketing Bayer, Levitra, erectile dysfunction
Bayer is to launch a new formulation of its erectile dysfunction drug Levitra. The European Commission granted Levitra (verdenafil HCI) …
Bayer signs Chinese research deal
July 20, 2010Research and Development Bayer, China, gynaecology
Bayer is partnering with the People’s Liberation Army General Hospital in Beijing on research into women’s healthcare. The People’s Liberation …
Bayer launches world’s first cannabis-derived prescription drug
June 21, 2010Sales and Marketing Bayer, GW Pharmaceuticals, Sativex
Bayer Healthcare has launched the world’s first cannabis-derived prescription drug in the UK. Sativex treats the spasticity symptoms of multiple …
Nexavar fails in lung cancer trial
June 15, 2010Research and Development Bayer, NSCLC, Nexavar, Onyx
Bayer and Onyx Pharmaceutical’s oncology drug Nexavar has failed to meet its primary endpoint in a phase III study for …
Bayer opens US ‘science hub’
May 18, 2010Research and Development Bayer, US, acdemia, clinical research
Bayer Schering Pharma has expanded its global research network, opening a new Innovation Center in San Francisco. The US centre …
Bayer colon cancer drug moves into phase III
May 11, 2010Research and Development Bayer, colorectal cancer, regorafenib
Bayer Schering Pharma will shortly begin phase III tests of its investigational compound regorafenib for patients with metastatic colorectal cancer. …
Bayer lures Novartis’ Reinhardt for top healthcare post
April 22, 2010Research and Development, Sales and Marketing Bayer, appointment, research and development, sales and marketing
German pharma company Bayer has ended its search for someone to replace healthcare chief executive Arthur Higgins, appointing Dr Jörg …
Bayer pharma sales overcome European decline
February 26, 2010Sales and Marketing 2009 financials, Bayer, Xarelto
Bayer’s group sales dropped 5% to 31 billion euros in a “difficult year” for the company that saw a drop …
Digital Pharma: Glucose monitoring for the Nintendo generation
January 20, 2010Medical Communications Bayer, diabetes, digi, digi game, digital pharma
The Nintendo DS that arrived in our house on Christmas has already become my eldest son’s most favourite present of …
Digital Pharma: A Year in Digital (4/5)
December 15, 2009Medical Communications 2009, Bayer, digi, digital pharma, year in review
Favourite use of digital (pharma)Physicians’ social networks. This is pharma’s new engagement channel offering the industry an opportunity to normalise …
Bayer takes Alzheimer’s diagnostic into pivotal trials
December 2, 2009Research and Development Alz, Bayer, diagnostic
An imaging agent that can detect amyloid plaques in the brains of Alzheimer’s patients and so may provide an accurate …
Latest content
